Co-Authors
This is a "connection" page, showing publications co-authored by Eliza Chakravarty and Joan Merrill.
Connection Strength
0.874
-
Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018; 5(1):e000258.
Score: 0.155
-
Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
Score: 0.142
-
How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford). 2014 Dec; 53(12):2175-81.
Score: 0.118
-
Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Sci Med. 2014; 1(1):e000005.
Score: 0.118
-
Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013 Nov; 40(11):1875-80.
Score: 0.114
-
Serologic markers of Epstein-Barr virus reactivation are associated with increased disease activity, inflammation, and interferon pathway activation in patients with systemic lupus erythematosus. J Transl Autoimmun. 2021; 4:100117.
Score: 0.049
-
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
Score: 0.045
-
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
Score: 0.045
-
Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study. EClinicalMedicine. 2020 Mar; 20:100291.
Score: 0.044
-
Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures. Lupus Sci Med. 2019; 6(1):e000365.
Score: 0.044